Literature DB >> 12438452

Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.

Lydie Cassard1, Joël F G Cohen-Solal, Annie Galinha, Xavier Sastre-Garau, Claire Mathiot, Jérôme Galon, Thierry Dorval, Alain Bernheim, Wolf H Fridman, Catherine Sautès-Fridman.   

Abstract

The efficacy of anti-tumor IgG reflects the balance between opposing signals mediated by activating and inhibitory Fc(gamma) receptors (Fc(gamma)Rs) expressed by effector cells. Here, we show that human malignant melanoma cells express the inhibitory low-affinity Fc(gamma) receptor Fc(gamma)RIIB1 in 40% of tested metastases. When melanoma cells were grafted in nude mice, a profound inhibition of Fc(gamma)RIIB1 tumor growth that required the intracytoplasmic region of the receptor was observed. IgG immune complexes (ICs) may be required for this inhibition, since sera from nude mice bearing tumors contained IgG that decreased the proliferation of Fc(gamma)RIIB1-positive cells in vitro, and tumor development of Fc(gamma)RIIB1-positive melanoma lines was not inhibited in antibody-defective severe combined immunodeficiency (SCID) mice. Passive immunization of SCID mice with anti-ganglioside G(D2) antibody resulted in significant inhibition of growth of Fc(gamma)RIIB1-positive tumors in an intracytoplasmic-dependent manner. Altogether, these data suggest that human melanoma cells express biologically active inhibitory Fc(gamma)RIIB1, which regulates their development upon direct interaction with anti-tumor antibodies. Therefore, Fc(gamma)R expression on human tumors may be one component of the efficacy of antibody-mediated therapies, and Fc(gamma)R-positive tumors could be the most sensitive candidates for such treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438452      PMCID: PMC151807          DOI: 10.1172/JCI15454

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

Review 1.  The occurrence, structural and functional properties of immunoglobulin Fc receptors on murine neoplastic cells.

Authors:  C Neauport-Sautes; M Daëron; J L Teillaud; U Blank; W H Fridman
Journal:  Int Rev Immunol       Date:  1986-07       Impact factor: 5.311

2.  New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells.

Authors:  N Gross; D Beck; J Portoukalian; S Favre; S Carrel
Journal:  Int J Cancer       Date:  1989-04-15       Impact factor: 7.396

3.  Common human melanoma-associated antigen(s) detected by monoclonal antibodies.

Authors:  S Carrel; R S Accolla; A L Carmagnola; J P Mach
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

4.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Tumor-bound immunoglobulins. I. Further analysis of the characteristics of binding of immunoglobulins to in vivo-grown tumor cells.

Authors:  G Dorval; I P Witz; E Klein; H Wigzell
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

6.  Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

Authors:  L D Cahan; R F Irie; R Singh; A Cassidenti; J C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Human monocytes and U937 cells bear two distinct Fc receptors for IgG.

Authors:  R J Looney; G N Abraham; C L Anderson
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

8.  A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes.

Authors:  K Pulford; E Ralfkiaer; S M MacDonald; W N Erber; B Falini; K C Gatter; D Y Mason
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

9.  Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.

Authors:  Samareh Azeredo da Silveira; Shuichi Kikuchi; Liliane Fossati-Jimack; Thomas Moll; Takashi Saito; J Sjef Verbeek; Marina Botto; Mark J Walport; Michael Carroll; Shozo Izui
Journal:  J Exp Med       Date:  2002-03-18       Impact factor: 14.307

10.  Human melanoma antigen AH is an autoantigenic ganglioside related to GD2.

Authors:  T Watanabe; C S Pukel; H Takeyama; K O Lloyd; H Shiku; L T Li; L R Travassos; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake.

Authors:  Sabrina Lisi; Margherita Sisto; Dario Domenico Lofrumento; Simona D'Amore; Massimo D'Amore
Journal:  Clin Exp Med       Date:  2010-05-09       Impact factor: 3.984

2.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 3.  Fc receptors as adaptive immunoreceptors.

Authors:  Marc Daëron
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

Review 4.  Fc gamma receptors and cancer.

Authors:  Lydie Cassard; Joël Cohen-Solal; Sophie Camilleri-Broët; Emilie Fournier; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Springer Semin Immunopathol       Date:  2006-11-10

5.  Effects of CD40 binding on ovarian carcinoma cell growth and cytokine production in vitro.

Authors:  O Toutirais; A Gervais; F Cabillic; M Le Gallo; A Coudrais; J Levêque; V Catros-Quemener; N Genetet
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

Review 6.  Inhibitory Fc gamma receptors: from gene to disease.

Authors:  Radu N Stefanescu; Mikhail Olferiev; Yi Liu; Luminita Pricop
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

7.  Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.

Authors:  Joel F G Cohen-Solal; Lydie Cassard; Emilie M Fournier; Shannon M Loncar; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Dermatol Res Pract       Date:  2010-06-28

8.  Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.

Authors:  Branka Petricevic; Johannes Laengle; Josef Singer; Monika Sachet; Judit Fazekas; Guenther Steger; Rupert Bartsch; Erika Jensen-Jarolim; Michael Bergmann
Journal:  J Transl Med       Date:  2013-12-12       Impact factor: 5.531

Review 9.  Fc gamma receptors: glycobiology and therapeutic prospects.

Authors:  Jerrard M Hayes; Mark R Wormald; Pauline M Rudd; Gavin P Davey
Journal:  J Inflamm Res       Date:  2016-11-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.